DOYLESTOWN, Pa., Jan. 23 /PRNewswire-FirstCall/ -- The Quigley Corporation announced today that their Scientific Advisory Board, composed of 12 highly regarded medical professionals as well as three additional guest attendees, met to review 2005 research and development results and were extremely encouraged by the findings. As such, the Advisory Board has indicated that they strongly support Quigley Pharma’s research and development efforts and advocate their next stage of development.
The Scientific Advisory Board was given an update of all data and research results of compounds in development acquired over the last 12 months including QR-333 (Diabetic Neuropathy), QR-336 (Radio protective-Ionizing Radiation), QR-435 (Antiviral-Avian Influenza), QR-440 (Anti-inflammatory) and QR-442 (Multiple Sclerosis). This was the 4th annual meeting of the Scientific Advisory Board, which took place in Philadelphia on January 6.
Joseph C. Arezzo, Ph.D., Professor Neuroscience and Neurology, and a guest to the board, commented on QRR-440 anti-inflammatory study results, “The EAE model has a long history and the results obtained with Quigley Pharma’s compound are striking. The findings are as impressive as any that I have seen.”
Phillip A. Low, the chairman of the division of clinical neurophysiology at The Mayo Clinic in Rochester, Minnesota stated, “Dr. Ron’s experimental model presents surprising preliminary evidence that QR336 has potential as a systemic radio protective agent. Further studies are recommended.”
Philip Raskin, M.D., Professor of Medicine, Department of Internal Medicine, University of Texas added, “The preliminary data on these compounds has been encouraging and I would urge Quigley Pharma to continue its development efforts as quickly as possible.”
All Board Members attended the annual meeting. They include the following:
-- Nicholas Diamond, D.O. of the Diamond Pain Clinic, Elkins Park, Pennsylvania. Dr. Diamond is a researcher in pain and rehabilitation and an editorial board member of the American Journal of Pain Management; -- Mario Guralnik, Ph.D., president of Synergy Research, Inc, a professional independent clinical contract research organization specializing in clinical drug development; -- Edwin Keates, M.D., of Northern Ophthalmic Associates, Inc., Jenkintown, Pennsylvania. Dr. Keates’ research has been presented at the American Academy of Neurology and published in the Johns Hopkins Medical School journal Advanced Studies in Medicine; -- Peter Lodewick, M.D. of Lodewick Diabetes Center, Birmingham, Alabama. Dr. Lodewick, a diabetic research scientist and author of several books on diabetes; -- Phillip A. Low, M.B., B.S. (Syd.), M.D. (Syd.), F.R.A.C.P., FRCP, is the chairman of the division of clinical neurophysiology at The Mayo Clinic in Rochester, Minnesota. Dr. Low serves on the editorial board of numerous publications including Muscle & Nerve, Journal of the Autonomic Nervous System, Journal of Clinical Neurophysiology and Journal of Clinical Neuromuscular Diseases. He serves on the scientific advisory board of the Neuropathy Association and is a member of the steering committee-NIDDK/NHLBI Animal Models of Diabetic Complications Neuropathy Disease Validation Committee. Dr. Low is a co-author of “The Textbook of Diabetic Neuropathy"; -- Philip Raskin, M.D., Professor of Medicine, Department of Internal Medicine, University of Texas, Southwestern Medical Center at Dallas, Texas. Dr. Raskin serves as the editor of the Journal of Diabetes Complications and Director of the University of Diabetes Treatment Center/Parkland Memorial Hospital, Dallas, Texas. Guests of the Board in attendance were: -- Raymond Silk, M.D. Silk Clinic, Philadelphia PA; -- Professor Yacov Ron, Department of Molecular Genetics and Microbiology and Immunology at the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, NJ; -- Joseph C. Arezzo, Ph.D. Professor Neuroscience and Neurology, Albert Einstein College of Medicine; -- Robert Lambkin, Ph.D. of Retroscreen Virology, University of London, London, UK participating via teleconference.
The Quigley Corporation is the leading developer and marketer of diversified health products. The company’s proven success in launching first- in-category health solutions supports the Pharma subsidiary in its efforts to develop strong pharmaceutical compounds targeting diverse conditions such as diabetes and rheumatoid arthritis with naturally derived compounds and botanicals.
The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND for human study or take any other action to allow the aforementioned compounds to be marketed. Furthermore, no claim is made that the potential medicines discussed here are safe, effective, or approved by the Food and Drug Administration.
About The Quigley Corporation
The Quigley Corporation is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has four (4) wholly owned subsidiaries. Darius International markets health and wellness products through its wholly owned subsidiary, InnerLight Inc. Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities. Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived prescription drugs.
Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the company’s actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.
CONTACT: Media Investor Relations Karen Pineman Carl Hymans G.S. Schwartz & Co. G.S. Schwartz & Co. 212.725.4500 212.725.4500 kpineman@schwartz.comcarlh@schwartz.com
The Quigley Corporation
CONTACT: Media: Karen Pineman, +1-212-725-4500, kpineman@schwartz.com, orInvestor Relations: Carl Hymans, +1-212-725-4500, carlh@schwartz.com, bothof G.S. Schwartz & Co., for The Quigley Corporation
